Small Cap Network Blog

No real surprises here…we mentioned this micro cap biotech stock was probably moving for a reason, and today our guess was confirmed. MIV Therapeutics (MIVT) presented some impressive news at Transcatheter Cardiovascular Therapeutics (TCT) conference being held this week in Washington, D.C. The VESTASYNC heart stent - the one they’ve been working on forever - seems to be safe as well as effective, at least at the four-month mark.

In 13 of the 15 patients implanted with the hydroxyapatite-coated stent, the results and physical impact of the stent are well within acceptable tolerances. Most importantly, there’s no evidence of thrombosis whatsoever. That was the key goal behind the stent’s coating, as other coated stents have recently been implicated in major problems with post-stent-implant complications…most thrombosis.

Though I’m no biotechnician, this sounds very encouraging. I know four months isn’t a long time, but considering they bothered to present anything at all this soon tells me it’s worthy data. The efficacy to-date has been good enough to merit the planning of a wider-scale test of the same stent. 

The stock was actually off a little today in the wake of the news. However, I also think the blast-off from a month ago was ultimately driven by this news - even before it was official.

At this point I believe the next milestone for MIVT is at 70 cents and 74 cents. We saw a handful of peaks there earlier in the year. If we can get past that zone with this recent push, maybe MIVT will be one of our Cinderella stories for 2007.

Click here for the news release

Are you a subscriber to the Small Cap Network newsletter? If not, you’re missing out on some great trading ideas and exclusive market commentary. To sign up, just go to the top right corner of any page of our website. You’ll be joining thousands of other subscribers who have already benefited from our news and views.